IL6 and neoplasm: IL-17A promotes the expression of IL-6, G-CSF, MFG-E8, and CXCL1 in NSCLC tumor tissues to increase tumor-associated neutrophils (TANs) infiltration and reduce the number of tumor-infiltrating lymphocytes (TILs), leading to drug resistance to PD-1 inhibitors [13].